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Abstract
Schistosoma infection is a poverty-related parasitic infection, being the second most
important neglected tropical disease in the world after malaria. Schistosomiasis is
caused by five distinct Schistosoma species distributed in tropical and subtropical
areas. But, imported cases can also be seen in non - endemic areas. Human popula‐
tions acquire infection after exposure to contaminated water collections. Schistosoma
infection falls on a large spectrum of clinical manifestations that ranges from absence
of signs and symptoms to severe forms of disease. Although morbidity and mortality
have been reduced along the years after use of mass drug administration (MDA) in
endemic areas, large populations are still at risk of disability-related outcomes on dai‐
ly basis. Recently, a great deal of debate has been done over two main issues in schis‐
tosomiasis management in endemic and non-endemic areas: how to accurately
diagnosis Schistosoma infections pre and post-therapy in addition to assess morbidity
level. Adoption of promising new diagnostic tools and development of new markers
of disease progression might change the current scenario by improving schistosomia‐
sis clinical management in both community and institutional settings.
Keywords: schistosomiasis, diagnostic tests, markers of therapy response, morbidity,
community settings, institutional settings
1. Introduction
Schistosoma infection is a poverty-related parasitic infection, being the second most important
neglected tropical disease in the world after malaria. Schistosomiasis is a blood-fluke-induced
infection, which may present with acute and chronic disease forms. Schistosomiasis is caused
by five distinct Schistosoma species distributed in tropical and subtropical areas. However,
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imported cases can also been seen in nonendemic areas. Human populations acquire infection
after exposure to contaminated fresh water sources like dams, rivers, canals, lakes, and
streams. Schistosoma infection falls on a large spectrum of clinical manifestations that ranges
from absence of signs and symptoms to severe forms of disease. Although morbidity and
mortality have been reduced along the years after use of mass drug administration (MDA) in
endemic areas, large populations are still at risk of disability-related outcomes on a daily basis.
A broad spectrum of clinical manifestations and also asymptomatic infections are observed [1,
2]. Three major species, Schistosoma haematobium, Schistosoma japonicum, and Schistosoma
mansoni, and another two minor species, Schistosoma mekongi and Schistosoma intercalatum, are
recognized as the mainly pathogenic Schistosoma species that infect human populations [3, 4].
Parasite transmission occurs after contamination of water collections with Schistosoma eggs
eliminated by infected individuals, which further develop in the infective form called cercariae
in freshwater snails. The release of Schistosoma cercariae from snails is followed by skin
penetration of the definitive hosts (human and nonhuman species like buffalos in the case of
S. japonicum or rodents in the case of S. mansoni infection). In the latter, Schistosoma immature
forms evolve to adults that lay eggs, which are spread in the definitive hosts and/or eliminated
in the environment through excreta, like urine in the case of S. haematobium and stool for the
other species. In some areas, nonhuman definitive hosts are also essential to maintain
Schistosoma life cycle, such as buffalos for S. japonicum and rodents for S. mansoni [5, 6].
Schistosomiasis world distribution is essentially in tropical and subtropical areas, with more
than 90% of infected individuals living in sub-Saharan Africa [7, 8]. However, imported cases
of schistosomiasis are also becoming increasingly frequent in nonendemic areas such as
Europe. Spotlights were thrown on schistosomiasis in the recent years since elimination is
believed to be a reachable goal for some endemic regions on the globe. Education, sanitation
policies, and hygiene awareness proved to promote a high impact on infection transmission
[9]. Also, field work in different transmission areas shows that chemotherapy plays an evident
role in decreasing prevalence, parasite burden, and late morbidity [10].
Recently, a great deal of debate has been done over two main issues in schistosomiasis
management in endemic and nonendemic areas: how to accurately diagnosis Schistosoma
infections before and after therapy in addition to assess morbidity level. The adoption of
promising new diagnostic tools and the development of new markers of disease progression
might change the current scenario by improving schistosomiasis clinical management in both
community and institutional settings.
The diagnosis of active Schistosoma infection is based on the demonstration of egg excretion
by parasitological methods such as Kato-Katz (K-K), which has a low cost and can be per‐
formed in field studies. Direct egg detection achieves 100% specificity and high sensitivities
parallel with high parasite burden. However, in individuals with less than 100 eggs per gram
(epg), parasitological method loses sensitivity. Non-egg excretors are usually underdiagnosed.
Furthermore, the assessment of cure rate is unreliable postchemotherapy use [11, 12]. More‐
over, the evaluation of the effectiveness of schistosomiasis control or eradication programs
after (mass) chemotherapy is distorted. New approaches have been developed and proposed
as complementary or in substitution to K-K. New approaches such as DNA detection assays
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and rapid tests have evolved in the last years [13]. The accurate assessment of schistosomiasis
diagnosis, morbidity determination, and therapy response through new technologies became
suitable for use in both institutional as well as community settings. The upgrade of diagnostic
technology that encompasses the detection of active infection before chemotherapy and
monitoring of treatment response will permit advances in public health policies as well as in
individual clinical management [14, 15]. Moreover, the assessment of clinical presentation, the
disease stage, and the prognosis have been the object of progresses that go side by side with
the development of new image diagnostic apparatus. Also, biochemical, immunological, and
molecular markers have been tested for the evaluation of fibrosis, vascular damage, and even
cancer [16]. The present review aims to discuss the new surveillance strategies and their impact
on schistosomiasis clinical management.
2. New diagnostic tools in both community and institutional settings
The laboratory investigation of Schistosoma infection consists of different techniques, including
parasitological, immunological, and molecular biology methods [17-19]. Frequently, diagnos‐
tic approaches are also applied on the monitoring of drug response. In addition, the assessment
of morbidity levels can be achieved by using image tests and biochemical markers [20-22].
However, the diagnosis of active Schistosoma infection and the monitoring of therapy response
as well as the determination of morbidity levels are distinctively assessed at community and
institutional settings (Figure 1). Furthermore, in community settings, conventional or investi‐
gational tools aim to assess the efficiency of national control programs in the morbidity control
and/or elimination of transmission by measuring the prevalence and intensity of infection in
intermediary and definitive hosts [23-25]. In contrast, in institutional settings, diagnostic
approaches aim to improve clinical management of individual cases.
Traditionally, egg detection by microscopy is the major criteria for active Schistosoma infection
[24, 26]. Egg excretion can be detected by parasitological methods such as urine filtration and
centrifugation methods in the case of S. haematobium. Since S. japonicum, S. mansoni, S. mekon‐
gi, and S. intercalatum eggs are shed in the feces, egg patent infection is detected in fecal samples
by parasitological methods such as Kato-Katz test (K-K). The principal characteristics of K-K
are as follows: an easy-to-do technique, low cost, reliability, and accurate identification of eggs
in the case of Schistosoma species. Also, parasitological methods are quantitative. As a result,
parasite load can be estimated. Egg counts correlate with the intensity of being <100 eggs per
gram (epg), >100-399 epg, and >400 epg designated as light, moderate, and severe infection,
respectively, according to WHO guidelines. Furthermore, the assessment of morbidity levels
can also be roughly determined. Based on findings in high endemic areas, the elevated number
of eggs was associated with severe forms of disease. Both urine filtration and Kato-Katz test
have been applied for diagnosis and monitoring therapy response and used in field studies in
areas of transmission as well as in institutional settings. Although Kato-Katz are affordable
and suitable for low-income areas with individuals presenting with heavy to moderate
infections, Schistosoma infection diagnosis can be quite tricky to detect in individuals with acute
schistosomiasis or light infection living in nonendemic and low-endemic areas when based
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solely on microscopy [27]. Lack of egg shedding, one gender-induced infection, and daily
variability are some of the causes that directly interfere with the sensitivity of microscopy, thus
compromising the detection of Schistosoma infection and resulting in the underestimation of
“real prevalence” [15, 28]. Moreover, the erratic elimination of Schistosoma eggs makes the
determination of therapy response uncertain. In addition, some patients may present with
severe forms of disease such as neuroschistosomiasis or genital schistosomiasis without any
egg excretion detectable [13]. Strategies to overcome the lack of sensitivity of urine filtration
and Kato-Katz test include testing replicate samples of urine or stool samples and/or aug‐
menting the number of Kato-Katz slides/sample [29].
Other parasitological methods such as sedimentation, centrifugation, flotation techniques, and
miracidium hatching were developed and had improved the diagnosis of light infections by
increasing sensitivity [26, 32]. In institutional settings, tissue biopsy such as rectal snips and
liver biopsy are largely used to diagnose active infection in non-egg excretors despite its
invasiveness [31]. Eventually, surgical specimens reveal previously undiagnosed schistoso‐
Figure 1. Schistosomiasis flowchart for clinical management in community and institutional settings. Conventional
and new tools to diagnosis, determination of response to therapy, and morbidity assessment are indicated under com‐
munity and institutional settings in hierarchic order. Bellow conventional tests, new tools were depicted according to
the strength of literature evidence (red boxes). Approaches still under investigation and/or diagnostic platforms that
show debatable results are inside the gray boxes. PM: parasitological method; US: ultrasonography; PCR: polymerase
chain reaction; RDT: rapid test (POC-CCA /POC-CAA); FOB: fecal occult blood; CT: computed tomography; MRI:
magnetic resonance imaging.
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miasis. Except for rectal snips, histological examination is not quantitative, lack of information
on parasite burden does not preclude clinical assistance.
Albeit the availability of diverse parasitological methods and tissue biopsies as alternatives to
the reference test (Kato-Katz), nonparasitological methods were also developed to overcome
microscopy false-negative results. This is the case of immunological tests, which have become
more useful for showing active infections in recently exposed individuals, such as travelers or
chronically infected immigrants residing in nonendemic areas [32]. In areas of transmission,
immunodiagnosis is a suitable tool for surveillance in low endemic areas [29]. Several immu‐
nodiagnostic tests were developed, but currently the ELISA-based assays using egg antigen,
cercarial, or adult worm antigens have been extensively used [33]. In addition, recombinant
proteins and peptides have been potential targets [34-36]. Despite its infrequent use in National
Programs for Schistosomiasis Control, serology is a potent auxiliary diagnostic approach that
permits the diagnosis of non-egg excretors. However, the presence of active infection may be
undermined by persistent reactivity despite successful treatment [13, 29]. Although immu‐
noreactivity does not correlate with the intensity of infection, data have demonstrated that
isotypic immunoresponse may reflect morbidity levels [37, 38].
Moreover, rapid tests (RDT) for the detection of Schistosoma antigens like circulating cathodic
(CCA) and anodic (CAA) antigens and DNA detection assays have proven to be an advanced
and feasible strategy for diagnosing Schistosoma infection despite the absence of their use as
routine diagnostic approaches [13, 39]. See detailed comments in Table 1. During active
infection, gut-produced Schistosoma glycoproteins - POC-CCA and POC-CAA - are detectable
in the blood, urine, and stool. At individual level, results revealed that both CAA and CCA
ELISA-based assays can be quite sensitive to detect active infection early after exposure in
travelers even in the cases of light infections. Also, the tests allow a quantitative assessment of
antigen levels, which correlates with the intensity of infection [40]. Point-of-care platforms
(POC) have been applied to estimate infection prevalence with high accuracy in field studies
in high and moderate endemic areas [41, 42]. Although research groups claim that CCA and
CAA might be a suitable substitute for Kato-Katz test, its performance is still debatable in low
endemic areas [43, 44]. RDT for hematuria (urogenital schistosomiasis), fecal occult blood
(FOB), and calprotectin detection (entero-schistosomiasis) are also point-of-care approaches,
which have been shown to have fair association with egg-patent infections with dual use as
diagnostic tools and markers of morbidity [25, 45]. Although strong evidences support the
usage of hematuria detection by RDTs, larger studies are still necessary to establish the
usefulness of FOB and/or calprotectin detection in cases of light infection commonly found in
low endemic areas.
3. Assessment of morbidity and drug response in community and
institutional settings
Sanitation and community health education in addition to chemotherapeutic intervention are
measures that effectively contribute to the control and/or elimination of Schistosoma infection
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in several endemic areas and the resolution or attenuation of progressive forms of disease at
individual level [10, 46, 47]. However, the determination of the effects of these measures, in
particular, drug intervention, still presents as a challenge (Table 1). Tests like microscopy have
low sensitivity and underestimate cure rates especially in non-egg excretors. Day-to-day
variations in egg excretion contribute to the misdiagnosis of schistosomiasis elimination after
treatment [15]. The evaluation of drug response in individuals previously diagnosed by tissue
biopsies is also troubled since the procedures might be invasive like brain or spinal cord
biopsies in neuroschistosomiasis [48]. In immunoreactive egg and non-egg excretors submitted
to PZQ treatment, it was shown that reactivity against several proteins mostly related to
parasite musculature or glycolytic metabolism is enhanced after therapy [49]. Immunoreac‐
tivity might persist for long periods of time despite effective drug response, although sero‐
conversion may occur in some individuals. Nonetheless, in low-endemic areas,
immunodiagnosis has proven to be a valuable tool for schistosomiasis surveillance [50].
Changes in immunoreactivity in controlled areas can be used as an indicator of maintained
transmission and/or active infection in community settings [51]. Therefore, the assessment of
drug response is a hot topic in the schistosomiasis and development of new tools became an
urgent matter (Table 1). Investigations have shown a potential role in drug response assess‐
ment with the use of rapid tests and DNA detection assays [14, 52].
Traditional Tools Investigational Tools
Community
Settings
Tests Characteristics/Observations Tests Characteristics / Observations
Vector control Light Exposure
Test
(Cercarial
shedding
detection)
For determination of
transmission control,
elimination or erradication.
Inaccurate. no species
identification; Test does not
detect prepatent infections; no
assessment of early post-control
measures in snail infection rates.
Antigen
Detection
Detection in 2nd week post-infection
(pi); secretion by live larvae; group
specific. Not commercially available
assays.
DNA- based
assays
Detection in 1st week pi; quantitation
of parasite load (real -time PCR;
specie-specific identification.
Mapping foci of vector snails and
monitoring transmission. In house
assays.
Non-human
Hosts
Parasitological
Methods
(Egg detection)
Traditional methods which are
simple, cheap and effective for
Schistosoma detection.
CCA-dipsticks
(urine lateral
flow test)
Serology (IgG/
IgM)
Detection of active infection
independent of patent egg-excretion
in primate non-humans. Only
determination of genus but not
species.
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Traditional Tools Investigational Tools
Community
Settings
Tests Characteristics/Observations Tests Characteristics / Observations
Defines exposure to Schistosoma. In
chimpanzee populations serology
present high sensitivity but reactivity
may persist for years after infection
has been cleared.
Comercial available test.
Humans Hosts
Sanitation /
Education
Questionaries
Parasitological
Methods
(Egg detection)
Serology
Questionnaries are applied to
identify high - risk populations
and permits assessment of
Schistosoma infection
Parasitological tests are
quantitative methods. Low price
per test. Used for Screening
sentinel populations like school
children.See more comments
below.
DNA- based
assays1
Identification and mapping of
Schistosoma endemic areas.
DNA based assays are powerful
tools for detection of Schistosoma
active infections. DNA detection
show better performance even in
light infection (low parasite loads)
or despite absence of egg excretion.
Mostly tested in “small” studies.
Chemotherapy Parasitological
Methods
(Egg detection)
Microscopy is highly sensitive
and specific to detect egg-patent
infections. Day-to-day
variations on egg excretion is a
limitation. Absence of egg
excretion post-treatment may
not represent response to
therapy. Cure rates determined
in different S. mansoni and
S.haematobium infections are
variable (49.2 to 98.40%) [53, 54].
Understimates reinfection and
also incomplete cure.
DNA-based
assays1
DNA detection has higher
sensitivity after use of
chemotherapy. Persistent DNA
amplification in both egg excretors
and non-egg excretors strongly
suggest no response to therapy.
Presents good performance
compared to parasitological
methods to determine effect of
MDA. Cure rates calculated by
different DNA - based assays in
distinct populations and by different
Schistosoma species may varie from
21.1 - 30.7 to 75.6% [55, 15].
Persistence of DNA amplification
until 6 months and post- 6 months
after treatment might suggest
incomplete infection and reinfection,
respectively DNA-based assays for
Schistosoma infection detection are
not currently commercially
available.
Serology Loss of sensitivity of
microscopy has been replaced in
Rapid Test POC-CCA maintains higher
sensitivity than parasitological
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Traditional Tools Investigational Tools
Community
Settings
Tests Characteristics/Observations Tests Characteristics / Observations
some control programs by
serology which may remain
reactive for extended periods
post effective drug use. In areas
submitted to several rounds of
chemotherapy, low and/or
absence of reactivity might
represent control of
infection.Long periods of
obsevation are necessary to
determine Schistosoma infection
“real status”. Reinfection or
incomplete cure may not be
assessed.
methods after PZQ use. However,
specificity may be compromised by
the presence of persistent low
reactivity ( trace positive samples)
post-chemotherapy.Cure rates may
vary from 23.3 - 26.1 to 40.7- 47.8%
[42, 54]
Institutional
Settings
Chemotherapy Parasitological
Methods
(Egg detection)
Assessment of post-therapy
response by parasitological
methods in clinical wards has
similar advantages and
limitations as in community
settings. In immigrants (long
gone from endemic areas) and
recently exposed travelers,
absence of egg excretion pre-
therapy represent an obstacle.
Ova detection is inappropriate
to determine therapy response
in these groups. See above other
coments.
DNA-based
assays1
DNA-based assays are a reliable tool
to detect response to therapy in
distinct clinical specimens. Absence
of DNA amplification correlates
with response to therapy in
individuals treated in Travel
Medicine Clinics
[56].In case of therapy failure,
maintained DNA amplification
correlate with persistence of clinical
signs, symptoms and pathological
abnormalities associated to therapy
failure [57]. Usefulness of DNA-
based assays to detect past infection
incomplete cure for non re-exposed
individuals has to be established
with large studies [58].
Tissue Biopsy No viable eggs in rectal snips
show good correlation with
response to therapy. However,
tissue biopsy (rectal snips, liver
biopsies) are invasive
procedures. And, lack of ova
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Traditional Tools Investigational Tools
Community
Settings
Tests Characteristics/Observations Tests Characteristics / Observations
detection may not represent
absence of active infection [59].
Serology Immunoreactivity persistence
for years after effective therapy
is the major limitation. Negative
seroconversion representes
response to therapy and it is
observed in some individuals
[56]. But, assessment of therapy
failure is mostly difficult [59].
Transplant Tissue Biopsy Donnor and organ-recipients
from endemic areas with /
without transaminase
alterations can be screened by
tissue biopsy [60]. But, negative
tissue samples do not rule out
active infection.
DNA- based
assays1
Further studies are necessary.
1DNA based assay - conventional PCR, real-time PCR and LAMP (Loop-mediated isothermal amplification)
Table 1. Effectiveness of interventions in surveillance programs and monitoring therapy response in clinical
management: use of traditional and investigational tools.
RDTs for antigen detection have been largely used for population studies to evaluate post‐
therapy response and efficacy [42, 43]. In areas of moderate and high endemicity, therapy
response represented by decrease or disappearance of antigen detection may represent cure.
However, in light infections, rapid test accuracy is reduced with maintained antigen detection
in individuals without infection. The use of antigen detection assays is a debatable matter to
measure posttherapy response. In contrast, DNA assays seem to be a suitable marker of drug
response. Cure is determined by the absence of DNA amplification postchemotherapy use,
while persistent DNA amplification correlates with nonresponse to therapy [15].
Schistosomiasis presents as a large spectrum of manifestations and disease severity during
acute and chronic phases. Usually, imaging tests and/or biological markers are required to
confirm diagnosis, to assess morbidity, and to stage disease progression [21, 22]. Image tests
such as ultrasonography became revolutionary to assess urogenital S. haematobium infection
and S. mansoni liver disease [61]. In both community and institutional settings, conventional
ultrasound (US) examination is a well-standardized test to assess bladder and liver fibrosis,
which is the hallmark of disease progression in urinary and intestinal schistosomiasis,
respectively [62-65]. US predicts disease prevalence rates and is a reliable noninvasive
indicator of morbidity levels which aloud disease staging [64, 66]. However, morbidity
measurement in a multivariate clinical manifestation infection like schistosomiasis is no easy
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task. Targeting one compartment to measure schistosomiasis morbidity might not be enough
since some clinical presentations can affect a single compartment like in neuroschistosomiasis
and others. In intestinal Schistosoma infection, independent hepatosplenic forms are the most
common clinical presentation after asymptomatic S. mansoni infection. However, in contrast
to hepatic schistosomiasis, the study of disease progression by using image and/or biochemical
markers is still poorly developed [21]. Promising new approaches such as capsule endoscopy
have been introduced, but large-scale studies are still necessary to evaluate the usefulness of
the method [67]. In hepatosplenic forms, vascular gastropathy and colopathy can be indicators
of portal hypertension severity [68]. The assessment of vascular alterations in superior
gastrointestinal tract are used to determine schistosomiasis levels of morbidity through the
use of upper digestive endoscopy in association with conventional ultrasonography and
Doppler imaging [66]. In institutional settings, transient elastography, magnetic resonance,
and computerized tomography might give supplementary information regarding fibrosis
progression and vascular status, although standardization is necessary especially for disease
staging [22, 69]
4. Conclusion
In community settings, concerns have been increasing on the effectiveness of schistosomiasis
control interventions like MDA over the years. The low accuracy of the reference test to detect
active Schistosoma infection and the improper estimates of cure rates jeopardize the truthful
analysis of drug intervention, which compromises the effectiveness of surveillance systems.
In clinical settings, underdiagnosed schistosomiasis and inadequate morbidity assessment also
increase the burden on public and private health systems. In order to change this scenario,
new diagnostic tools, markers of treatment response, and morbidity assessment have been
developed over the years showing promising results. Nonetheless, efforts still have to be made
to find a single cheap and easy-to-do approach that is suitable and reliable for diagnosis,
treatment evaluation, and disease staging in community and institutional settings.
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